GO
Loading...

Results hurt by patent expirations: Eli Lilly CEO

Thursday, 24 Jul 2014 | 7:07 AM ET

John Lechleiter, Eli Lilly CEO, breaks down the pharmaceutical giant's quarterly results. And Lechleiter weighs in on the benefits of investing in R&D.